ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate for evorpacept combo in HER2-positive gastric cancer
Bitget2026/09/28 12:04- ALX Oncology reported already-published Phase 2 ASPEN-06 data in Nature Medicine for evorpacept in previously treated HER2-positive gastric cancer.
- The regimen delivered stronger tumor shrinkage and longer-lasting benefit than standard therapy, with the largest gains in a biomarker-defined subgroup.
- Findings supported CD47 expression as a potential patient-selection marker, reinforcing the company’s biomarker-driven development strategy.
- ALX chose not to pursue a U.S. registrational Phase 3 path in gastric cancer, shifting focus toward potential partnerships for that program.
- Management kept its mid-2027 target for a topline readout from 80 patients in the ongoing Phase 2 ASPEN-09-Breast trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
